AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin

Core Insights - AbbVie has completed the acquisition of Gilgamesh Pharmaceuticals' investigational candidate, bretisilocin, which is in Phase 2 development for treating major depressive disorder (MDD) [1][3]. Group 1: Acquisition Details - The acquisition enhances AbbVie's psychiatry pipeline with a next-generation psychedelic compound aimed at addressing challenges associated with classic psychedelic treatments [1][2]. - Bretisilocin is a short-acting serotonin 5-HT2A receptor agonist and 5-HT releaser, currently in Phase 2 clinical trials for moderate-to-severe MDD [2]. Group 2: Clinical Development and Commitment - Recent clinical results indicate bretisilocin's potential effectiveness in treating patients with MDD, reinforcing AbbVie's commitment to innovative treatment options for serious mental health conditions [3]. - AbbVie aims to accelerate the development of bretisilocin following the acquisition, highlighting its focus on science-driven solutions in neuroscience [3]. Group 3: Company Overview - AbbVie's mission is to discover and deliver innovative medicines that address serious health issues across various therapeutic areas, including neuroscience [4].